This article was originally published in The Gray Sheet
Executive SummaryRefractive laser firm raises $16 mil. via investments of $8 mil. each by Dawson Samberg Capital Management Funds and TLC The Laser Center, Inc. -both consisting of 2 mil. shares of preferred stock at $4 each. The firm received an additional $4.3 mil. on June 5 in connection with the sale of Vision Twenty-One stock received last December in connection with that firm's acquisition of two of LaserSight's health care subsidiaries ("The Gray Sheet" Jan. 5, In Brief). Proceeds will be used for expansion of the firm's international presence and for U.S. marketing activities, as well as debt repayment and repurchase of all Series B preferred stock. LaserSight and TLC are collaborating to develop a mobile excimer laser business...
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.